Skip to ContentSkip to Navigation
About us Practical matters How to find us prof. dr. G.N. (Gert) Moll


Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer

AT2 receptor agonist LP2 restores respiratory function in a rat model of bleomycin-induced lung remodelling

Evolving views on the first two ligands of the angiotensin II type 2 receptor. From putative antagonists to potential agonists?

Galanin 2 Receptor: A Novel Target for a Subset of Pancreatic Ductal Adenocarcinoma

LP2, a cyclic angiotensin-(1−7) analog extended with an N-terminal D-lysine, impairs growth of patient-derived xenografts of colorectal carcinoma in mice

LP2, a stable lanthipeptide derived from cAng-(1-7), exerts myeloprotective action in mice

Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake

LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study

An Engineered Double Lipid II Binding Motifs-Containing Lantibiotic Displays Potent and Selective Antimicrobial Activity against Enterococcus faecium

Biosynthesis of lanthionine-constrained agonists of G protein-coupled receptors

Read more


Uit RUG voortgekomen Lanthio Pharma Chemische Start-up van het Jaar